On October 22, 2015, Roche Holding AG (OTC: RHHBY) disclosed that its GATSBY trial assessing its product, Kadcyla (ado-trastuzumab emtansine), for second-line treatment of HER2-positive advanced gastric cancer did not meet its primary endpoint. Roche expects the detailed clinical findings from GATSBY to be reported at a future medical conference. Earlier this year, ImmunoGen, Inc. entered into a royalty purchase agreement that monetized the Company’s royalties on Kadcyla sales.
Help employers find you! Check out all the jobs and post your resume.
